Answers are grounded in this paper and cite their sources.
Algorithms identify deprioritized drug candidates in clinical trials, suggesting potential value for alternative development.
We propose a set of algorithms to identify 'shelved asset candidates' in drug development-drug candidates for which development was discontinued for reasons other than safety or efficacy. Using a variety of microdata sources and classification algorithms, we identify 5523 drug-development programs that appear to have been deprioritized after entering human clinical trials. While many of these assets were likely discontinued for scientifically valid reasons that may not be fully observable in public data, the analysis suggests that a subset may retain scientific or commercial option value under alternative development strategies. These estimates provide a starting point for building a systematic catalog of discontinued assets and for facilitating collaboration among industry sponsors, nonprofit organizations and new developers interested in repositioning or advancing these compounds.
No takes yet. Share an insight, caveat, or question.
Bakker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: